Feasibility of a group cessation program for co-smokers of cannabis and tobacco

Drug and Alcohol Review

Volumn 34, Issue 4, 2015, Pages 418-426

  Becker, Julia ^a   Haug, Severin ^a   Kraemer, Thomas ^a   Schaub, Michael P ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Cannabis; Co smoking; Dual cessation; Tobacco

Indexed keywords

ADULT; CANNABIS SMOKING; COGNITIVE THERAPY; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HUMAN; MALE; MARIJUANA ABUSE; MOTIVATIONAL INTERVIEWING; PREVENTION AND CONTROL; PROCEDURES; SMOKING; SMOKING CESSATION; TOBACCO USE DISORDER; YOUNG ADULT;

ADULT; COGNITIVE THERAPY; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MARIJUANA ABUSE; MARIJUANA SMOKING; MOTIVATIONAL INTERVIEWING; SMOKING; SMOKING CESSATION; TOBACCO USE DISORDER; YOUNG ADULT;

EID: 84942552441     PISSN: 09595236     EISSN: 14653362     Source Type: Journal    
DOI: 10.1111/dar.12244     Document Type: Article

References (48)

1. Hall W, Degenhardt L. Adverse health effects of non-medical cannabis use. Lancet 2009;374:1383-1391.
2. Caldeira KM, Grady KEO, Vincent KB, Arria AM. Marijuana use trajectories during the post-college transition: health outcomes in young adulthood. Drug Alcohol Depend 2012;125:267-275.
3. Lim SS, Vos T, Flaxman AD, etal. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2224-2260.
4. Substance Abuse and Mental Health Services Administration (2013). Detailed data Table 6.9B-Types of illicit drug use in the past month among persons aged 18 to 25, by past month cigarettes use: percentages, 2011 and 2012. National Survey on Drug Use and Health, 2011 and 2012. Available at: http://www.samhsa.gov/data/sites/default/files/NSDUH-DetTabsPDFWHTML2013/Web/PDFW/NSDUH-DetTabsSect6peTabs7to10-2013.pdf (accessed October 2014).
5. Richter KP, Kaur H, Resnicow K, Nazir N, Mosier MC, Ahluwalia JS. Cigarette smoking among marijuana users in the United States. Subst Abus 2005;25:35-43.
6. Agrawal A, Budney AJ, Lynskey MT. The co-occurring use and misuse of cannabis and tobacco: a review. Addiction 2012;107:1221-1233.
7. Van Beurden EK, Zask A, Passey M, Kia AM. The Mull Hypothesis: is cannabis use contributing to high tobacco use prevalence among young North Coast males? N S W Public Health Bull 2008;19:72-74.
8. Banbury A, Zask A, Carter SM, etal. Smoking mull: a grounded theory model on the dynamics of combined tobacco and cannabis use among adult men. Health Promot J Austr 2013;24:143-150.
9. Patton GC, Coffey C, Carlin JB, Sawyer SM, Lynskey M. Reverse gateways? Frequent cannabis use as a predictor of tobacco initiation and nicotine dependence. Addiction 2005;100:1518-1525.
10. Baggio S, Deline S, Studer J, Mohler-Kuo M, Daeppen J-B, Gmel G. Routes of administration of cannabis used for nonmedical purposes and associations with patterns of drug use. J Adolesc Health 2014;54:235-240.
11. Ford DE, Vu HT, Anthony JC. Marijuana use and cessation of tobacco smoking in adults from a community sample. Drug Alcohol Depend 2002;67:243-248.
12. Abrantes AM, Lee CS, MacPherson L, Strong DR, Borrelli B, Brown RA. Health risk behaviors in relation to making a smoking quit attempt among adolescents. J Behav Med 2009;32:142-149.
13. Gourlay SG, Forbes A, Marriner T, Pethica D, McNeil JJ. Prospective study of factors predicting outcome of transdermal nicotine treatment in smoking cessation. Br Med J 1994;309:842-846.
14. Moore BA, Budney AJ. Tobacco smoking in marijuana-dependent outpatients. J Subst Abuse 2001;13:583-596.
15. De Dios MA, Vaughan EL, Stanton CA, Niaura R. Adolescent tobacco use and substance abuse treatment outcomes. J Subst Abuse Treat 2009;37:17-24.
16. Ramo DE, Liu H, Prochaska JJ. Tobacco and marijuana use among adolescents and young adults: a systematic review of their co-use. Clin Psychol Rev 2012;32:105-121.
17. Peters EN, Budney AJ, Carroll KM. Clinical correlates of co-occurring cannabis and tobacco use: a systematic review. Addiction 2012;107:1404-1417.
18. Becker J, Hungerbuehler I, Berg O, etal. Development of an integrative cessation program for co-smokers of cigarettes and cannabis: demand analysis, program description, and acceptability. Subst Abuse Treat Prev Policy 2013;8:33.
19. Hill KP, Toto LH, Lukas SE, etal. Cognitive behavioral therapy and the nicotine transdermal patch for dual nicotine and cannabis dependence: a pilot study. Am J Addict 2013;22:233-238.
20. Dunn KE, Sigmon SC, Reimann E, Heil SH, Higgins ST. Effects of smoking cessation on illicit drug use among opioid maintenance patients: a pilot study. J Drug Issues 2009;39:313-327.
21. Nieva G, Ortega LL, Mondon S, Ballbè M, Gual A. Simultaneous versus delayed treatment of tobacco dependence in alcohol-dependent outpatients. Eur Addict Res 2011;17:1-9.
22. Mueller SE, Petitjean SA, Wiesbeck GA. Cognitive behavioral smoking cessation during alcohol detoxification treatment: a randomized, controlled trial. Drug Alcohol Depend 2012;126:279-285.
23. Baca CT, Yahne CE. Smoking cessation during substance abuse treatment: what you need to know. J Subst Abuse 2009;36:205-219.
24. Hall SM, Prochaska JJ. Treatment of smokers with co-occurring disorders: emphasis on integration in mental health and addiction treatment settings. Annu Rev Clin Psychol 2009;5:409-431.
25. Prochaska JJ, Delucchi K, Hall SM. A meta-analysis of smoking cessation interventions with individuals in substance abuse treatment or recovery. J Consult Clin Psychol 2004;72:1144-1156.
26. Miller WR, Rollnick S. Motivational interviewing: preparing people for change, 2nd edn. New York: Guilford Press, 2002.
27. Marlatt GA, Donovan DM, eds. Relapse prevention: maintenance strategies in the treatment of addictive behaviors, 2nd edn. New York: Guilford Press, 2005.
28. Annaheim B, Rehm J, Gmel G. How to screen for problematic cannabis use in population surveys: an evaluation of the Cannabis Use Disorders Identification Test (CUDIT) in a Swiss sample of adolescents and young adults. Eur Addict Res 2008;14:190-197.
29. Hjorthøj CR, Hjorthøj AR, Nordentoft M. Validity of Timeline Follow-Back for self-reported use of cannabis and other illicit substances-systematic review and meta-analysis. Addict Behav 2012;37:225-233.
30. Lee D, Huestis MA. Current knowledge on cannabinoids in oral fluid. Drug Test Anal 2013;6:88-111.
31. Adamson SJ, Sellman JD. A prototype screening instrument for cannabis use disorder: the Cannabis Use Disorders Identification Test (CUDIT) in an alcohol-dependent clinical sample. Drug Alcohol Rev 2003;22:309-315.
32. Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO. The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addict 1991;86:1119-1127.
33. Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA. The AUDIT alcohol consumption questions (AUDIT-C). An effective brief screening test for problem drinking. Arch Intern Med 1998;158:1789-1795.
34. Schmitt M, Altstötter-Gleich C, Hinz A, Maes J, Brähler E. Normwerte für das Vereinfachte Beck-Depressions-Inventar (BDI-V) in der Allgemeinbevölkerung. [Norms for the simplified Beck Depression Inventory (BDI-V) in a non-clinical population]. Diagnostica 2006;52:51-59.
35. Beck AT, Steer RA. Beck Depression Inventory (BDI). San Antonio: The Psychological Corporation Inc, 1987.
36. Margraf J, Ehlers A. Deutschsprachige Adaptation des Beck Anxiety Inventory [German Adaptation of the Beck Anxiety Inventory (BAI)]. Bern: Huber, 1995.
37. Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol 1988;56:893-897.
38. Twisk JWR. Applied longitudinal data analysis for epidemiology: a practical guide, 2nd edn. Cambridge: Cambridge University Press, 2013.
39. Arndt S. Stereotyping and the treatment of missing data for drug and alcohol clinical trials. Subst Abuse Treat Prev Policy 2009;4:2.
40. IBM Corp. IBM SPSS Statistics 20.0, Armonk, NY, USA. 2011.
41. Denis C, Lavie E, Fatseas M, Auriacombe M. Psychotherapeutic interventions for cannabis abuse and/or dependence in outpatient settings. Cochrane Database Syst Rev 2006;(3):CD005336.
42. Budney AJ, Roffman R, Stephens RS, Walker D. Marijuana dependence and its treatment. Addict Sci Clin Pract 2007;4:4-16.
43. Stephens RS, Roffman RA, Simpson EE. Treating adult marijuana dependence: a test of the relapse prevention model. J Consult Clin Psychol 1994;62:92-99.
44. Jorenby DE, Smith SS, Fiore MC, etal. Varying nicotine patch dose and type of smoking cessation counseling. JAMA 1995;274:1347-1352.
45. Brown RA, Niaura R, Lloyd-Richardson EE, etal. Bupropion and cognitive-behavioral treatment for depression in smoking cessation. Nicotine Tob Res 2008;9:721-730.
46. Camarelles F, Asensio A, Jiménez-Ruiz C, Becerril B, Rodero D, Vidaller O. Efectividad de la intervención grupal para la deshabituación tabáquica. Ensayo clínico aleatorizado. [Effectiveness of a group therapy intervention to quit smoking. Randomized clinical trial]. Med Clin (Barc) 2002;119:53-57.
47. Hjorthøj CR, Fohlmann A, Larsen A-M, Arendt M, Nordentoft M. Correlations and agreement between delta-9-tetrahydrocannabinol (THC) in blood plasma and timeline follow-back (TLFB)-assisted self-reported use of cannabis of patients with cannabis use disorder and psychotic illness attending the CapOpus randomized clinical trial. Addiction 2012;107:1123-1131.
48. Robinson SM, Sobell LC, Sobell MB, Leo GI. Reliability of the Timeline Followback for cocaine, cannabis, and cigarette use. Psychol Addict Behav 2014;28:154-162.